TheraRadar
← Back
Data updated: Jun 28, 2026

ARROWHEAD

Pharma
Infectious DiseaseCardiovascularRespiratory Execution: Needs Improvement

ARROWHEAD is a pharmaceutical company focused on Infectious Disease, Cardiovascular, Respiratory. Key products include REDEMPLO.

2025
Since
1
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
1 Small Molecules

FDA Novel Drug Designations

(2025)
1 Novel 1 First-in-Class 1 Orphan 1 Breakthrough 1 Fast Track
See 1 novel approval →
2025 REDEMPLO (PLOZASIRAN SODIUM) First-in-Class · Orphan · Breakthrough · Fast Track

ARROWHEAD at a Glance

  • Fast trial execution (24 months median completion)

ARROWHEAD's Key Drugs

ARROWHEAD's core commercial portfolio centers on REDEMPLO, spanning Infectious Disease and Cardiovascular — its most strategically important drugs approved in the last 15 years.

REDEMPLO
Metabolic

Familial Chylomicronemia Syndrome

ApoC-III mRNA Approved 2025

ARROWHEAD's Recent FDA Approvals

ARROWHEAD secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

REDEMPLO NDA
2025-11-18
plozasiran sodium
Familial Chylomicronemia Syndrome

ARROWHEAD's Therapeutic Areas

ARROWHEAD's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Cardiovascular, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 45%
0 drugs Phase 2: 7 Phase 1: 3
Cardiovascular 29%
0 drugs Phase 3: 2 Phase 2: 1 Phase 1: 1
Respiratory 18%
0 drugs Phase 2: 1 Phase 1: 5
Metabolic 5%
0 drugs Phase 1: 2
Neurology 3%
0 drugs Phase 1: 1

ARROWHEAD Pipeline Snapshot

ARROWHEAD has 23 active clinical programs from ClinicalTrials.gov — 2 Phase 3, 9 Phase 2 and 12 Phase 1.

2
Phase 3
9
Phase 2
12
Phase 1

Phase 3 Readout Calendar Pro

4 Phase 3 trials with confidence-graded primary completion dates.

Full calendar →
Q3 2027
zodasiran Injection
Homozygous Familial Hypercholesterolemia
Estimated · fresh NCT07037771
Q3 2028
Plozasiran Injection
Hypertriglyceridemia
Estimated · fresh NCT06822790
Q3 2028
Zodasiran
Homozygous Familial Hypercholesterolemia
Estimated · fresh NCT07473843
Unlock 1 more readouts with confidence-graded estimates
Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • REDEMPLO leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Infectious Disease pipeline focus
  • • 4 Phase 3 readouts tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 0/8 completed
  • • Speed: 24 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges